DRG Epidemiology's coverage of RSV comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report both the incidence and prevalence of RSV infection for each country as well as annualized case counts projected to the national population.
DRG Epidemiology's RSV forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, and the launch of the RSV vaccine affect the epidemiology of RSV over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following RSV subpopulations:
Event Rate of Respiratory Syncytial Virus per 1,000 People of All Ages in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in Events of Respiratory Syncytial Virus Over the Next 20 Years
Analysis of the Events of Respiratory Syncytial Virus in 2021, by Age
Epidemiology Data
Methods
Diagnosed Events: Inpatients
Diagnosed Events: Outpatients
Pediatric Patient Populations, by Risk Group
Singleton Pregnancies
Gestational Age
Reference Materials
Literature Review
Studies Included in the Analysis of Respiratory Syncytial Virus
Studies Excluded From the Analysis of Respiratory Syncytial Virus
Risk/Protective Factors
Risk/Protective Factors for Respiratory Syncytial Virus
Bibliography
Abbreviation Table
Glossary
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.
